A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 5, Issue 8, Pages e335-e335
Publisher
Springer Nature
Online
2015-08-07
DOI
10.1038/bcj.2015.63
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of cytokines in the initiation and progression of myelofibrosis
- (2013) Hans C. Hasselbalch CYTOKINE & GROWTH FACTOR REVIEWS
- Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
- (2013) J V Jovanovic et al. LEUKEMIA
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy
- (2012) Feng Fang et al. ARTHRITIS RESEARCH & THERAPY
- Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis
- (2011) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- What are RBC-transfusion-dependence and -independence?
- (2010) R.P. Gale et al. LEUKEMIA RESEARCH
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Advances in Understanding and Management of Myeloproliferative Neoplasms
- (2009) A. M. Vannucchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pleiotropism of Adiponectin
- (2009) Guido Krenning et al. CIRCULATION RESEARCH
- Myeloproliferative disorders
- (2008) R. L. Levine et al. BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors
- (2008) Ifat Geron et al. CANCER CELL
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now